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Chronic obstructive pulmonary disease (COPD) is characterized by symptoms of cough,
sputum and breathlessness, which become worse during acute exacerbations. The airway
inflammation associated with COPD has led to trials of the effect of systemic
corticosteroids in COPD assessed in two Cochrane systematic reviews. In stable COPD,
compared with placebo, oral corticosteroid treatment increased mean FEV1 by 53ml and
mean 12-min walking distance by 29m, but at an increased risk of any drug-related adverse
event (OR 7.8). In acute exacerbations, oral corticosteroid treatment decreased the
chance of treatment failure (OR 0.48), improved mean FEV1 at 72 h by 140ml and improved
arterial blood gases, but increased the risk of drug-related adverse events (OR 2.3). Thus,
treatment of stable and acute exacerbations of COPD with systemic corticosteroids results
in statistically significant average benefits, but at an increased risk of adverse events. In
stable COPD, there is little support for the use of systemic corticosteroid treatment, as
data on long-term outcomes are lacking. For acute exacerbations, the evidence to support
the use of systemic corticosteroids is stronger, but further research is required to define
the optimum dose, route and duration.
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Chronic obstructive pulmonary disease (COPD) is a progres-
sive disorder of the airways, including airway inflammation,
resulting in airflow limitation that is not fully reversible.
Most international guidelines define COPD as the presence of
persistent airflow limitation after bronchodilator adminis-
tration usually defined as a (1) reduced forced expiratory
volume in 1 s (FEV1)/forced vital capacity (FVC) ratio less
than 0.7; and (2) evidence of exposure to a recognized
aetiological agent, most notably cigarette smoking. It
presents a considerable health burden within the developed
world, and causes significant morbidity to individuals with
the disorder. The characteristic long-term clinical features
of the disorder, predominantly cough, sputum and breath-
lessness, become intermittently worse during episodes
known as acute exacerbations. Most of these are thought
to occur as a result of infections, either bacterial or viral in
origin.1 The increased symptoms during acute exacerba-
tions2 are mirrored by worsening of airway inflamma-
tion. The huge effect of acute exacerbations on the quality
of life of people with COPD has increasingly been recog-
nized,3 and considerable resources are devoted to prevent-
ing their occurrence and reducing their effect when they
do occur.
The presence of airway inflammation in COPD, knowledge
of the anti-inflammatory effects of corticosteroids, and the
established effect of corticosteroids in treating other forms
of airway inflammation, most notably asthma, have led to
trials of the effect of systemic corticosteroids in COPD. Oral
corticosteroids have a range of anti-inflammatory actions
that are mediated by genomic and non-genomic mechan-
isms.4 This overview aims to summarize the effects of
systemic corticosteroids in COPD from two Cochrane
systematic reviews assessing chronic stable5 and acute
exacerbations6 of the disease. The Cochrane Database
of Systematic Reviews, contained within the Cochrane
Library, is a resource produced to inform and support
health-care delivery. Systematic reviews are prepared by
members of the Cochrane Collaboration, and use a
systematic approach to identify data from the literature,
undertake independent assessments of its validity, extract
relevant data for inclusion in meta-analysis and summarize
the results. As a result of their rigour and objectivity,7
Cochrane reviews are usually allocated the highest level in
grading evidence.Oral corticosteroids in stable chronic
obstructive pulmonary disease
The review on stable COPD5 was first published in 2005 and
was based on a wide search strategy using a combination of
COPD and adrenal cortex hormones or related terms. A total
of 24 studies involving 1029 participants were identified, of
which five were parallel-group design and 19-crossover
design. Of the crossover studies, eight did not use a washout
period between treatments. Prednisolone was the oral
corticosteroid used in all but one study (between 30 and
40mg daily in 83% of participants), most often for 2 weeks’
duration. For studies with a crossover design, outcome data
from the first treatment period were used where available,
or an appropriate statistical method was used to calculate
an overall effect and associated variance. Study participants
were expected to have a diagnosis of COPD based on
objective criteria, including persistent airflow limitation
after bronchodilator administration, a history of cigarette
smoking and exclusion of asthma. A minimum of 1 month of
disease stability, without exacerbation of symptoms or use
of systemic steroids, was stipulated, and co-interventions
needed to be matched for both groups. A range of outcomes
was measured across the studies, including symptom scores
or health-related quality of life, lung function, functional
capacity, acute exacerbations and adverse effects.Lung function
The FEV1 was the most frequently reported outcome across
studies, and could be combined from 14 short duration
studies (p3 weeks) involving 396 participants (Fig. 1). At
the end of the treatment period, the weighted mean
difference (WMD) between oral corticosteroid treatment
and placebo was 53.3 (95% confidence interval [CI]
22.2–84.3) ml favouring oral corticosteroids. The range in
the mean difference across studies was large (from
47–180ml). A single study was of adequate duration to
allow the decline in FEV1 to be measured,
8 but was
complicated by the co-administration of inhaled budesonide
to two of the three arms. No statistically significant
difference was found between interventions, with a median
change in FEV1 of 30 (range 180–870) ml per year for oral
placebo and inhaled budesonide, compared with 40 (range
340–60) ml per year for oral prednisolone and inhaled
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Review: Oral Corticosteroids for stable Chronic Obstructive Pulmonary Disease
Comparison: 01 Oral steroid versus placebo- short term <= 3 weeks
Outcome: 01 FEV1 (ml) all studies
Study  WMD (fixed) Weight  WMD (fixed)
or sub-category  WMD (SE)  95% CI %  95% CI
01 High dose oral steroid
Blair 1984 72.0000  (97.3902) 2.65 72.00   [-118.88, 262.88]
Brightling 2000 70.0000  (33.1633) 22.87 70.00   [5.00, 135.00] 
Corden 1998 40.0000  (45.9184) 11.93 40.00   [-50.00, 130.00]
Davies 2000 51.0000  (66.9158) 5.62 51.00   [-80.15, 182.15]
Eliasson 1986 112.0000  (60.5000) 6.87 112.00    [-6.58, 230.58] 
Lam 1983 180.0000  (85.0000) 3.48 180.00    [13.40, 346.60]
Mendella 1982 140.0000  (91.8367) 2.98 140.00    [-40.00, 320.00]
Mitchell 1984 150.0000  (56.1225) 7.99 150.00    [40.00, 260.00]
Morgan 1964 64.4000  (290.1837) 0.30 64.40   [-504.35, 633.15]
O'Reilly 1982 4.0000  (106.4000) 2.22 4.00   [-204.54, 212.54]
Strain 1985         100.0000  (142.8571) 1.23 100.00    [-179.99, 379.99]
Syed 1991           -47.0000   (86.1684) 3.39 -47.00     [-215.89, 121.89]
Weir 1993           -7.0000   (30.2400) 27.51 -7.00    [-66.27, 52.27]
Subtotal (95% CI) 99.06 54.19   [22.96, 85.43]
Test for heterogeneity: Chi² = 13.05, df = 12 (P = 0.37), I² = 8.0%
Test for overall effect: Z = 3.40 (P = 0.0007)
02 Low dose oral steroid
Evans 1974           -40.0000 (163.2653) 0.94 -40.00 [-359.99, 279.99]
Subtotal (95% CI) 0.94 -40.00 [-359.99, 279.99]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
Total (95% CI) 100.00 53.30 [22.21, 84.39]
Test for heterogeneity: Chi² = 13.38, df = 13 (P = 0.42), I² = 2.8%
Test for overall effect: Z = 3.36 (P = 0.0008)
 -1000  -500 0  500  1000
 Favours placebo  Favours oral steroid
Figure 1 The effect of oral corticosteroids on FEV1 in stable chronic obstructive pulmonary disease.
Review: Oral Corticosteroids for stable Chronic Obstructive Pulmonary Disease
Comparison: 01 Oral steroid versus placebo- short term <= 3 weeks                                                         
Outcome: 03 > 20% response to treatment in FEV1                                                                        
Study  OR (fixed)  Weight  OR (fixed)
or sub-category  log[OR] (SE)  95% CI  %  95% CI
01 High dose oral steroid
Beerel 1963            1.2993 (1.1371)   3.07      3.67 [0.39, 34.05]       
Morgan 1964            0.8267 (1.1688)   2.90      2.29 [0.23, 22.59]       
Mendella 1982          0.9656 (0.4039)  24.31      2.63 [1.19, 5.80]        
O'Reilly 1982          0.0000 (0.8839)   5.08      1.00 [0.18, 5.65]        
Blair 1984             1.0750 (0.8605)   5.36      2.93 [0.54, 15.82]       
Mitchell 1984          0.8518 (0.3938)  25.57      2.34 [1.08, 5.07]        
Eliasson 1986          1.2238 (1.0847)   3.37      3.40 [0.41, 28.50]       
Mitchell 1986          1.0869 (0.4921)  16.37      2.97 [1.13, 7.78]        
Weir 1990              2.0490 (0.6869)   8.40      7.76 [2.02, 29.82]       
Syed 1991              0.6360 (0.8433)   5.58      1.89 [0.36, 9.86]        
Subtotal (95% CI) 100.00      2.72 [1.84, 4.02]
Test for heterogeneity: Chi² = 4.12, df = 9 (P = 0.90), I² = 0%
Test for overall effect: Z = 5.03 (P < 0.00001)
Total (95% CI) 100.00      2.72 [1.84, 4.02]
Test for heterogeneity: Chi² = 4.12, df = 9 (P = 0.90), I² = 0%
Test for overall effect: Z = 5.03 (P < 0.00001)
 0.001  0.01  0.1  1  10  100  1000
 Favours placebo  Favours oral steroid
Figure 2 The likelihood of having a X20% improvement in FEV1 in response to oral corticosteroids compared with placebo.
Systemic corticosteroids in COPD 373budesonide. Ten studies that defined a significant response
to corticosteroids as a greater than 20% improvement in
FEV1 from baseline (Fig. 2) found significantly greater oddsfor oral corticosteroid, with an OR of 2.7 (95% CI 1.8–4.0).
Using a background FEV1 response rate of 0.13 from the
placebo arms, this gives a number needed to treat (NNT) of
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R. Wood-Baker et al.3747 (95% CI 5–12) (i.e. seven people need to receive treatment
with oral corticosteroid to achieve one additional response
of an improvement in FEV1 of greater than 20%).
Quality of life
Symptom scores were reported in three studies, but it was
not possible to combine measurements as different scales
were used in the studies. No study found a statistically
significant difference between oral corticosteroid and
placebo interventions. Participants’ health-related quality
of life was measured by the chronic respiratory question-
naire (CRQ) in three studies, but even here incomplete
reporting did not allow aggregation of the overall score.
However, it was possible to combine results for individual
domains of the CRQ from these studies, which showed no
significant difference for dyspnoea or mastery. A statistically
significant benefit favouring oral corticosteroid was found
for fatigue (WMD 0.33, 95% CI 0.12–0.54) and emotional
function (WMD 0.21, 95% CI 0.06–0.37), although neither of
these reached a clinically relevant level.9
Functional capacity
Functional capacity was most commonly measured using the
12-min walking distance, but the three studies reported this
in different ways. For this to be combined across the
studies, a standardized mean difference was calculated
expressing changes in units of variance. The standardized
mean difference (SMD) between interventions was 0.44 (95%
CI, 0.14–0.74), equivalent to an increased walking distance
of 29m (95% CI 9.1–48.2), favouring oral corticosteroid.
Brightling et al.10 used the shuttle walking test and also
found a statistically significant difference between inter-
ventions; oral corticosteroids produced a mean improve-
ment of 12.6m (95% CI 3.8–21.5). In contrast, Strain et al.11
used oxygen consumption as an assessment of exercise
capacity and failed to find a statistical difference between
interventions. A clinically significant difference has not been
established for the 12-min walking test, but the 29m
improvement is less than the 54m, established as being
clinically relevant for the shorter 6-min test.12 No studies
found oral corticosteroids to have any significant effect on
rates of acute exacerbations of COPD. However, the
duration of follow-up in most studies is inadequate for this
outcome, and any evidence of effect for oral corticoster-
oids, for or against, is lacking.
Adverse effects
Of the 24 studies identified, only three reported overall
treatment-related events. Combining these found an in-
creased risk for participants allocated to oral corticosteroid;
the OR for any adverse event was 7.7 (95% CI 2.3–25.7)
compared with placebo. The most commonly reported
adverse effects were glucose intolerance and mild hyper-
tension. Using an event rate of 2% calculated from the
placebo arms, the number needed to harm (NNH) was 9 (i.e.
one additional adverse event for every nine people treated
with oral corticosteroids). Studies also showed significantchanges in serum osteocalcin, blood glucose levels, and
fasting morning plasma cortisol.
Summary
Although oral corticosteroids have been used in managing
stable COPD for many years, there is limited evidence to
support their efficacy. The main findings of the Cochrane
systematic review were that, compared with placebo, oral
corticosteroid treatment resulted in (1) an improvement in
lung function a mean increase in FEV1 at the end of
treatment of 53ml and an increased chance of a greater
than 20% increase in FEV1 (OR 2.7); (2) an increase in the
mean 12-min walking distance of 29m; and (3) an increased
risk of any drug-related adverse event (OR 7.8).
Systemic corticosteroids in acute
exacerbations of chronic obstructive
pulmonary disease
The review on systemic corticosteroids in acute exacerba-
tions of COPD6 was originally published in 1998, and most
recently updated in November 2004. The search strategy
aimed to identify randomized placebo-controlled trials of
oral or parenteral corticosteroids, using the search term
adrenal cortex hormone or related terms, for treatment of
an acute functional deterioration in people with COPD. The
original review included eight suitable studies, and a further
two studies were identified and included in the 2004 update.
Of these 10 studies, one was published in Abstract form only
and contained no data. No response to requests for further
information was received, so it could not contribute to the
analyses. For the remaining nine studies, five involved
patients admitted to hospital only, two involved participants
seen as outpatients and two received intervention in the
Emergency Department, with subsequent admission only if
required. A total of 951 participants were included in the
studies; most were men, but criteria confirming the
diagnosis of COPD were not uniformly reported. A range of
corticosteroid interventions were used, varying in duration
from 4 days to 8 weeks, using various administration routes
and doses. Outcomes varied between studies, and included
lung function, arterial blood gases, mortality, length of
hospital stay, functional status, treatment failure and
adverse drug effects.
Treatment failure
This was the primary outcome for the review, defined in
different ways between studies, including the need for
additional treatment, admission to hospital, intensification
of pharmacological treatment or requirement for assisted
ventilation. Seven studies involving 805 patients contributed
to the meta-analysis of this outcome (Fig. 3). They found
that treatment with systemic corticosteroids decreased the
risk of treatment failure compared with placebo (OR 0.48,
95% CI 0.34–0.68). To support this finding, the risk of relapse
within 30 days was also significantly less for corticosteroid
treatment from two large studies involving 415 participants
(hazard ratio 0.78, 95% CI 0.63–0.97). Using a baseline
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Review: Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease
Comparison: 01 Corticosteroid vs Placebo                                                                                  
Outcome: 01 Treatment failure                                                                                          
Study  Corticosteroid  Placebo  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Study design good
 Thompson 1996              0/13               8/14          8.53      0.03 [0.00, 0.57]        
 Davies 1999                1/29               5/27          5.39      0.16 [0.02, 1.44]        
 Niewoehner 1999           37/160             37/111        36.20      0.60 [0.35, 1.03]        
 Maltais 2002               3/62               8/66          7.95      0.37 [0.09, 1.46]        
 Aaron 2003                19/70              30/70         23.56      0.50 [0.24, 1.01]        
Subtotal (95% CI) 334                288  81.62      0.46 [0.31, 0.68]
Total events: 60 (Corticosteroid), 88 (Placebo)
Test for heterogeneity: Chi² = 5.31, df = 4 (P = 0.26), I² = 24.7%
Test for overall effect: Z = 3.93 (P < 0.0001)
02 Study design not optimal
 Emerman 1989               8/38               4/32          3.70      1.87 [0.51, 6.89]        
 Bullard 1996               5/60              14/53         14.69      0.25 [0.08, 0.76]        
Subtotal (95% CI) 98                 85  18.38      0.58 [0.27, 1.25]
Total events: 13 (Corticosteroid), 18 (Placebo)
Test for heterogeneity: Chi² = 5.26, df = 1 (P = 0.02), I² = 81.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Total (95% CI) 432                373 100.00      0.48 [0.34, 0.68]
Total events: 73 (Corticosteroid), 106 (Placebo)
Test for heterogeneity: Chi² = 10.66, df = 6 (P = 0.10), I² = 43.7%
Test for overall effect: Z = 4.14 (P < 0.0001)
 0.001  0.01  0.1  1  10  100  1000
 Favours treatment  Favours placebo
Figure 3 The risk of treatment failure with corticosteroid treatment compared with placebo.
Review: Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease
Comparison: 01 Corticosteroid vs Placebo                                                                                  
Outcome: 05 Early FEV1 (litres)                                                                                        
Study  Corticosteroid  Placebo  WMD (fixed)  Weight  WMD (fixed)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
Albert 1980             22      0.96(0.24)          22      0.86(0.31)      15.13      0.10 [-0.06, 0.26]       
Bullard 1996            60      0.66(0.59)          53      0.57(0.74)       6.55      0.09 [-0.16, 0.34]       
Thompson 1996           13      1.27(0.52)          14      0.91(0.31)       3.82      0.36 [0.03, 0.69]        
Wood-Baker 1997         18      0.82(0.38)          10      0.71(0.27)       6.90      0.11 [-0.13, 0.35]       
Davies 1999             29      0.96(0.48)          25      0.77(0.41)       7.20      0.19 [-0.05, 0.43]       
Niewoehner 1999        160      0.97(0.39)         111      0.87(0.39)      45.53      0.10 [0.01, 0.19]        
Maltais 2002            57      1.15(0.49)          58      0.90(0.41)      14.86      0.25 [0.08, 0.42]        
Total (95% CI)    359                         293 100.00      0.14 [0.08, 0.20]
Test for heterogeneity: Chi² = 4.75, df = 6 (P = 0.58), I² = 0%
Test for overall effect: Z = 4.27 (P < 0.0001)
 -1  -0.5  0  0.5  1
 Favours Placebo  Favours treatment
Figure 4 The benefit of systemic corticosteroids on FEV1 within 72 h of treatment.
Systemic corticosteroids in COPD 375treatment failure rate of 28%, calculated from the placebo
arms, this gives an NNT of 9 (95% CI 7–14) (i.e. nine patients
require treatment with systemic corticosteroids to avoid
one treatment failure).Lung function
Spirometry was the most commonly used lung function
measurement, but was carried out at various time points
across studies. For the purpose of meta-analyses, the time
points were divided into early (within 72 h of starting
treatment), and late (whatever the last measurement
beyond 72 h reported from the study). Six hundred and
fifty-two participants from seven studies contributed to the
early FEV1 outcome (Fig. 4), which showed a weighted mean
difference of 140 (95% CI 80–200) ml favouring corticoster-
oid treatment. A similar statistically significant benefit was
seen when the FEV1 was expressed as a percentage of
predicted values. However, the three studies reportingmeasurement of the FVC did not find a statistically
significant difference between interventions (WMD 190,
95% CI 60–450) ml. Fewer studies reported FEV1 measur-
ements472 h, with 537 participants contributing to the
meta-analysis. By this time point, the benefit of corticos-
teroid treatment had disappeared and there was no
significant difference between treatments, weighted mean
difference 30 (95% CI 40 to 100)ml.
Only two studies reported changes in arterial blood gas
concentrations; one measured all participants breathing
room air, and the other measured some participants
breathing supplementary oxygen. In order to overcome the
reporting difference, these were combined using a standar-
dized mean difference. Treatment with corticosteroids
resulted in a greater improvement in arterial oxygen
concentrations at 72 h compared with placebo; SMD 0.35
(95% CI 0.03–0.67) units. This was associated with a
statistically significant difference in the decrease in arterial
CO2 concentration at 72 h (WMD 0.91, 95% CI 1.13 to
0.69)mmHg, again favouring corticosteroid.
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Review: Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease
Comparison: 01 Corticosteroid vs Placebo                                                                                  
Outcome: 17 Adverse Drug Effect                                                                                        
Study  Corticosteroid  Placebo  OR (fixed)  Weight  OR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Albert 1980                2/22               3/22          8.09      0.63 [0.10, 4.22]        
 Emerman 1989               0/52               0/44                Not estimable         
 Thompson 1996              0/13               0/14                Not estimable         
 Wood-Baker 1997            0/18               0/10                Not estimable         
 Davies 1999                9/29               2/27          4.24      5.63 [1.09, 29.03]       
 Niewoehner 1999          113/160             51/111        52.46      2.83 [1.71, 4.69]        
 Maltais 2002              43/62              40/66         35.22      1.47 [0.71, 3.06]        
Total (95% CI) 356                294 100.00      2.29 [1.55, 3.38]
Total events: 167 (Corticosteroid), 96 (Placebo)
Test for heterogeneity: Chi² = 4.99, df = 3 (P = 0.17), I² = 39.9%
Test for overall effect: Z = 4.18 (P < 0.0001)
 0.01  0.1  1  10  100
 Favours treatment  Favours Placebo
Figure 5 The risk of an adverse event on systemic corticosteroid compared with placebo.
R. Wood-Baker et al.376Adverse effects
Adverse drug events were recorded in seven studies,
although in three of these no adverse drug effects were
reported for either intervention. There was a significantly
greater likelihood of having any adverse drug effect for
corticosteroid treatment compared with placebo (OR 2.3, 95
CI 1.6–3.3) (Fig. 5). A number of adverse effects associated
with corticosteroid steroid treatment were reported: the
most commonly reported was hyperglycaemia (three stu-
dies) (OR 5.48, 95% CI 1.58–18.96). A single study13 reported
a range of other specific adverse events, and found that
corticosteroid was more likely to cause an increase in
appetite, weight gain, and insomnia but no more likely to
cause anxiety or depression. Using data from the placebo
arms, the number needed to harm (NNH) was 6 (95% CI 4–10)
(i.e. one additional adverse effect occurred for every six
people treated).
Other outcomes
Mortality was reported in all nine studies, with no significant
difference between treatments (OR 0.85, 95% CI 0.45–1.59).
Scores for breathlessness were reported in three studies,
but using different measurements. The change in breath-
lessness at 72 h could be combined from two studies,
showing a statistically significant decrease in breathlessness
favouring corticosteroid compared with placebo (SMD 0.41,
95% CI 0.09–0.73) units. Although a number of studies
reported the length of hospital stay, these data could not be
combined in a meta-analysis. All three studies reporting this
found the overall duration of hospitalization was less for the
corticosteroid group compared with placebo, although this
reached statistical significance in only one of the three
studies.
Summary
The main findings of the Cochrane systematic review on the
effect of systemic corticosteroids in COPD exacerbations
were that, compared with placebo, oral corticosteroid
treatment resulted in (1) a lower chance of treatment
failure (OR 0.48); (2) a greater improvement in lung function(a mean difference in FEV1 at 72 h of 140ml); (3) a greater
improvement in arterial blood gases (standardized mean
difference in oxygen concentration of 0.35 units and a mean
difference in arterial CO2 concentration of 0.91mmHg);
(4) an increased risk of any drug-related adverse event
(OR 2.3).Conclusions
Treatment of both stable COPD and acute exacerbations in
COPD with systemic corticosteroid result in statistically
significant average benefits, but at an increased risk of
treatment-related adverse events. Do these benefits out-
weigh the risks? In acute exacerbations they probably do,
with less likelihood of treatment failure and clear early
benefit on FEV1 and arterial blood gases. Whether the
benefits on ventilatory function are relevant to all patients
in the era of very effective non-invasive ventilation14 is not
clear, as participants with acidosis requiring ventilation have
not been included in studies to date. Evidence of substantial
benefit during later hospitalization is also less clear. There is
no evidence of reduction in mortality, although findings on
length of stay have favoured corticosteroids. Given the
significantly increased risk of developing a drug-related
adverse event on corticosteroid, we should probably tailor
dose and duration to maximize benefits and minimize risks.
Unfortunately, there is little evidence to guide us here,
although one study found no significant difference between
2 and 8 weeks of corticosteroid treatment.15 Further
research is needed to identify the optimum dose, route
and duration of systemic corticosteroid treatment in
hospital and ambulatory settings, to establish whether the
benefits apply to participants receiving non-invasive venti-
lation, and to collect more data on longer-term outcomes.
The evidence to support the routine use of systemic
corticosteroids in stable COPD is much less convincing.
Although short-term treatment will improve the 12-min
walking distance, the average benefit is considerably less
than the minimal clinically significant difference for the 6-
min test. The benefit of the average 53ml improvement in
FEV1 is difficult to ascertain; but for every eight patients
treated with oral corticosteroids, one person will have a
greater than 20% improvement in the FEV1 (widely accepted
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Furthermore, evidence is lacking on whether short-term
treatment confers a long-term benefit, or, alternatively, if
long-term oral corticosteroid treatment is beneficial. Given
this absence of evidence of long-term benefit, their routine
use depends on the seriousness of the adverse effects, but it
is not in keeping with the high benefit to risk ratio previously
thought. Once again, further research with long-term
studies is required to clarify these issues, but there is little
evidence to justify traditional oral corticosteroid trials in
routine clinical practice.Practice points
 Systemic corticosteroids improve outcomes, parti-
cularly the likelihood of treatment failure, in acute
exacerbations of COPD
 Although oral corticosteroids improve lung function
in stable COPD, there is a significant cost in terms of
adverse drug effects
 The long-term risk–benefit ratio of oral corticoster-
oids in COPD is not knownResearch directions
 The benefits of corticosteroid treatment in people
admitted to hospital with an acute exacerbation of
COPD need to be more clearly defined
 The optimum duration of corticosteroid treatment
in acute exacerbations of COPD remains to be
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